Drug Profile

TGRX 3911

Alternative Names: TGRX-3911

Latest Information Update: 25 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shenzhen TargetRx
Class Antineoplastics; Small molecules
Mechanism of Action Agammaglobulinaemia tyrosine kinase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Haematological disorders

Most Recent Events

25 Jun 2025 TGRX 3911 is available for licensing as of 25 Jun 2025. https://www.tjrbiosciences.com/en/
25 Apr 2025 Preclinical trials in Haematological disorders in China (PO) before April 2025
25 Apr 2025 Pharmacodynamic and adverse events data from a preclinical trial in Haematological disorders presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com